Pseudohypoparathyroidism (PHP) is associated with biochemical hypoparathyroidism (i.e. hypocalcemia and hyperphosphatemia) due to parathyroid hormone (PTH) resistance rather than to PTH deficiency. Patients with PHP type 1a have a generalized form of hormone resistance plus a constellation of developmental defects termed Albright hereditary osteodystrophy (AHO). Within PHP type 1a families some individuals will show AHO but have normal hormone responsiveness, a variant phenotype termed pseudo-PHP. By contrast, patients with PHP type 1b manifest only PTH resistance and lack features of AHO. These various forms of PHP are due to defects in the GNAS1 gene that lead to decreased expression or activity of the α-subunit of the stimulatory G protein (Gsα). Tissue-specific genomic imprinting of GNAS1 accounts for the variable phenotypes of patients with GNAS1 defects.

Keywords:
G protein, Imprinting, Pseudohypoparathyroidism
1.
Albright F, Burnett CH, Smith PH: Pseudohypoparathyroidism: an example of ‘Seabright-Bantam syndrome’. Endocrinology 1942;30:922–932.
2.
Schipani E, Karga H, Karaplis AC, Potts JT Jr, Kronenberg HM, Segre GV, Abou-Samra AB, Juppner H: Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology 1993;132:2157–2165.
3.
Chase LR, Aurbach GD: Parathyroid function and the renal excretion of 3′5′-adenylic acid. Proc Natl Acad Sci USA 1967;58:518–525.
4.
Chase LR, Melson GL, Aurbach GD: Pseudohypoparathyroidism: Defective excretion of 3′,5′-AMP in response to parathyroid hormone. J Clin Invest 1969;48:1832–1844.
5.
Drezner MK, Neelon FA, Lebovitz HE: Pseudohypoparathyroidism type II: A possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973;280:1056–1060.
6.
Levine MA, Downs RW Jr, Singer MJ Jr, Marx SJ, Aurbach GD, Spiegel AM: Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. Biochem Biophys Res Commun 1980;94:1319–1324.
7.
Farfel Z, Brickman AS, Kaslow HR, Brothers VM, Bourne HR: Defect of receptor-cyclase coupling protein in pseudohypoparathyroidism. N Engl J Med 1980;303:237–242.
8.
Levine MA, Downs RW Jr, Moses AM, Breslau NA, Marx SJ, Lasker RD, Rizzoli RE, Aurbach GD, Spiegel AM: Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983;74:545–556.
9.
Germain-Lee EL, Ding CL, Deng Z, Crane JK, Saji M, Ringel MD, Levine MA: Paternal imprinting of Gαs in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun 2002;296:62–72.
10.
Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A: The Gsα gene: Predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 2002;87:4736–4740.
11.
Germain-Lee EL, Groman J, Crane JL, Jan de Beur SM, Levine MA: Growth hormone deficiency in pseudohypoparathyroidism type 1a: Another manifestation of multi-hormone resistance. J Clin Endocrinol Metab, in press.
12.
Kaji M, Umeda K, Ashida M, Tajima T: A case of pseudohypoparathyroidism type 1a complicated with growth hormone deficiency: Recovery of growth hormone secretion after vitamin D therapy. Eur J Pediatr 2001;160:679–681.
13.
Vlaeminck-Guillem V, D’herbomez M, Pigny P, Fayard A, Bauters C, Decoulx M, Wemeau JL: Pseudohypoparathyroidism Ia and hypercalcitoninemia. J Clin Endocrinol Metab 2001;86:3091–3096.
14.
Mann JB, Alterman S, Hills AG: Albright’s hereditary osteodystrophy comprising pseudohypoparathyroidism and pseudo-pseudohypoparathyroidism with a report of two cases representing the complete syndrome occurring in successive generations. Ann Intern Med 1962;56:315–342.
15.
Gomes MF, Camargo AM, Sampaio TA, Graziozi MA, Armond MC: Oral manifestations of Albright hereditary osteodystrophy: A case report. Rev Hosp Clin Fac Med São Paulo 2002;57:161–166.
16.
Levine MA: Hypoparathyroidism and pseudohypoparathyroidism; in Avioli LV, Krane SM (eds): Metabolic Bone Disease. San Diego, Academic Press, 1998, pp 501–529.
17.
Albright F, Forbes AP, Henneman PH: Pseudopseudohypoparathyroidism. Trans Assoc Am Physicians 1952;65:337–350.
18.
Levine MA, Jap TS, Mauseth RS, Downs RW, Spiegel AM: Activity of the stimulatory guanine nucleotide-binding protein is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: Biochemical, endocrine, and genetic analysis of Albright’s hereditary osteodystrophy in six kindreds. J Clin Endocrinol Metab 1986;62:497–502.
19.
Drezner MK, Haussler MR: Normocalcemic pseudohypoparathyroidism. Am J Med 1979;66:503–508.
20.
Levine MA, Modi WS, O’Brien SJ: Mapping of the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase (GNAS1) to 20q13.2–q13.3 in human by in situ hybridization. Genomics 1991;11:478–479.
21.
Kozasa T, Itoh H, Tsukamoto T, Kaziro Y: Isolation and characterization of the human Gs alpha gene. Proc Natl Acad Sci USA 1988;85:2081–2085.
22.
Leitner B, Lovisetti-Scamihorn P, Heilmann J, Striessnig J, Blakely RD, Eiden LE, Winkler H: Subcellular localization of chromogranins, calcium channels, amine carriers, and proteins of the exocytotic machinery in bovine splenic nerve. J Neurochem 1999;72:1110–1116.
23.
Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H, Fischer-Colbrie R: Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J Biol Chem 1997;272:11657–11662.
24.
Klemke M, Kehlenbach RH, Huttner WB: Two overlapping reading frames in a single exon encode interacting proteins – a novel way of gene usage. EMBO J 2001;20:3849–3860.
25.
Kehlenbach RH, Matthey J, Huttner WB: XLαs is a new type of G protein. Nature 1994;372:804–808.
26.
Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y, Bonthron DT: The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci USA 1998;95:10038–10043.
27.
Pasolli HA, Klemke M, Kehlenbach RH, Wang Y, Huttner WB: Characterization of the extra-large G protein alpha-subunit XLαs. I. Tissue distribution and subcellular localization. J Biol Chem 2000;275:33622–33632.
28.
Klemke M, Pasolli HA, Kehlenbach RH, Offermanns S, Schultz G, Huttner WB: Characterization of the extra-large G protein alpha-subunit XLαs. II. Signal transduction properties. J Biol Chem 2000;275:33633–33640.
29.
Bastepe M, Gunes Y, Perez-Villamil B, Hunzelman J, Weinstein LS, Juppner H: Receptor-mediated adenylyl cyclase activation through XLAS(s), the extra-large variant of the stimulatory G protein alpha-subunit. Mol Endocrinol 2002;16:1912–1919.
30.
Jan de Beur SM, Levine MA: Pseudohypoparathyroidism: Clinical, biochemical, and molecular features; in Bilezikian JP, Marcus R, Levine MA (eds): The Parathyroids: Basic and Clinical Concepts. San Diego, Academic Press, 2001, pp 807–826.
31.
Ishikawa Y, Tajima T, Nakae J, Nagashima T, Satoh K, Okuhara K, Fujieda K: Two mutations of the Gsα gene in two Japanese patients with sporadic pseudohypoparathyroidism type Ia. J Hum Genet 2001;46:426–430.
32.
de Sanctis L, Romagnolo D, Olivero M, Buzi F, Maghnie M, Scire G, Crino A, Baroncelli GI, Salerno M, Di Maio S, Cappa M, Grosso S, Rigon F, Lala R, de Sanctis C, Dianzani I: Molecular analysis of the GNAS1 gene for the correct diagnosis of Albright hereditary osteodystrophy and pseudohypoparathyroidism. Pediatr Res 2003;53:749–755.
33.
Pohlenz J, Ahrens W, Hiort O: A new heterozygous mutation (L338N) in the human Gsα (GNAS1) gene as a cause for congenital hypothyroidism in Albright’s hereditary osteodystrophy. Eur J Endocrinol 2003;148:463–468.
34.
Rickard SJ, Wilson LC: Analysis of GNAS1 and overlapping transcripts identifies the parental origin of mutations in patients with sporadic Albright hereditary osteodystrophy and reveals a model system in which to observe the effects of splicing mutations on translated and untranslated messenger RNA. Am J Hum Genet 2003;72:961–974.
35.
Farfel Z: Pseudohypoparathyroidism: A multitude of mutations in the stimulatory G protein alpha subunit (Gsα). J Pediatr Endocrinol Metab 2002;15:255–257.
36.
Lim SH, Poh LK, Cowell CT, Tey BH, Loke KY: Mutational analysis of the GNAS1 exons encoding the stimulatory G protein in five patients with pseudohypoparathyroidism type 1a. J Pediatr Endocrinol Metab 2002;15:259–268.
37.
Linglart A, Carel JC, Garabedian M, Le T, Mallet E, Kottler ML: GNAS1 lesions in pseudohypoparathyroidism Ia and Ic: Genotype phenotype relationship and evidence of the maternal transmission of the hormonal resistance. J Clin Endocrinol Metab 2002;87:189–197.
38.
Schwindinger WF, Francomano CA, Levine MA: Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992;89:5152–5156.
39.
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688–1695.
40.
Shenker A, Weinstein LS, Sweet DE, Spiegel AM: An activating Gsα mutation is present in fibrous dysplasia of bone in McCune-Albright syndrome. J Clin Endocrinol Metab 1994;79:750–755.
41.
Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM: Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs. J Pediatr 1993;123:509–518.
42.
Levine MA, Schwindinger WF, Downs RW Jr, Moses AM: Pseudohypoparathyroidism: Clinical, biochemical, and molecular features; in Bilezikian JP, Marcus R, Levine MA (eds): The Parathyroids: Basic and Clinical Concepts. New York, Raven Press, 1994, pp 781–800.
43.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L: GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692–696.
44.
Lyons J, Landis CA, Griffith H, Vallar L, Grunewald K, Feichtinger H, Yuh QY, Clark OH, Kawasaki E, Bourne HR, McCormick F: Two G protein oncogenes in human endocrine tumors. Science 1990;249:655–659.
45.
Schwindinger WF, Miric A, Zimmerman D, Levine MA: A novel Gsα mutant in a patient with Albright hereditary osteodystrophy uncouples cell surface receptors from adenylyl cyclase. J Biol Chem 1994;269:25387–25391.
46.
Warner DR, Gejman PV, Collins RM, Weinstein LS: A novel mutation adjacent to the switch III domain of G(Sα) in a patient with pseudohypoparathyroidism. Mol Endocrinol 1997;11:1718–1727.
47.
Warner DR, Weng G, Yu S, Matalon R, Weinstein LS: A novel mutation in the switch 3 region of Gsα in a patient with Albright hereditary osteodystrophy impairs GDP binding and receptor activation. J Biol Chem 1998;273:23976–23983.
48.
Wu WI, Schwindinger WF, Aparicio LF, Levine MA: Selective resistance to parathyroid hormone caused by a novel uncoupling mutation in the carboxyl terminus of Gαs: A cause of pseudohypoparathyroidism Type Ib. J Biol Chem 2001;276:165–171.
49.
Weinstein LS, Gejman PV, de Mazancourt P, American N, Spiegel AM: A heterozygous 4-bp deletion mutation in the Gsα gene (GNAS1) in a patient with Albright hereditary osteodystrophy. Genomics 1992;13:1319–1321.
50.
Yu S, Yu D, Hainline BE, Brener JL, Wilson KA, Wilson LC, Oude-Luttikhuis ME, Trembath RC, Weinstein LS: A deletion hot-spot in exon 7 of the Gs alpha gene (GNAS1) in patients with Albright hereditary osteodystrophy. Hum Mol Genet 1995;4:2001–2002.
51.
Ahmed SF, Dixon PH, Bonthron DT, Stirling HF, Barr DG, Kelnar CJ, Thakker RV: GNAS1 mutational analysis in pseudohypoparathyroidism. Clin Endocrinol (Oxf) 1998;49:525–531.
52.
Yokoyama M, Takeda K, Iyota K, Okabayashi T, Hashimoto K: A 4-base pair deletion mutation of Gs alpha gene in a Japanese patient with pseudohypoparathyroidism. J Endocrinol Invest 1996;19:236–241.
53.
Walden U, Weissortel R, Corria Z, Yu D, Weinstein L, Kruse K, Dorr HG: Stimulatory guanine nucleotide binding protein subunit 1 mutation in two siblings with pseudohypoparathyroidism type 1a and mother with pseudopseudohypoparathyroidism. Eur J Pediatr 1999;158:200–203.
54.
Nakamoto JM, Sandstrom AT, Brickman AS, Christenson RA, Van Dop C: Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsα gene mutation. Am J Med Genet 1998;77:261–267.
55.
Iiri T, Herzmark P, Nakamoto JM, Van Dop C, Bourne HR: Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Nature 1994;371:164–168.
56.
Miric A, Vechio JD, Levine MA: Heterogeneous mutations in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab 1993;76:1560–1568.
57.
Levis MJ, Bourne HR: Activation of the alpha subunit of Gs in intact cells alters its abundance, rate of degradation, and membrane avidity. J Cell Biol 1992;119:1297–1307.
58.
Levine MA: Pseudohypoparathyroidism; in Bilezikian JP, Raisz LG, Rodan GA (eds): Principles of Bone Biology. San Diego, Academic Press, 1996, pp 853–876.
59.
Wilson LC, Oude Luttikhuis ME, Clayton PT, Fraser WD, Trembath RC: Parental origin of Gs alpha gene mutations in Albright’s hereditary osteodystrophy. J Med Genet 1994;31:835–839.
60.
Davies SJ, Hughes HE: Imprinting in Albright’s hereditary osteodystrophy. J Med Genet 1993;30:101–103.
61.
Polychronakos C, Kukuvitis A: Parental genomic imprinting in endocrinopathies. Eur J Endocrinol 2002;147:561–569.
62.
Weinstein LS: The stimulatory G protein α-subunit gene: Mutations and imprinting lead to complex phenotypes. J Clin Endocrinol Metab 2001;86:4622–4626.
63.
Hayward BE, Moran V, Strain L, Bonthron DT: Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins. Proc Natl Acad Sci USA 1998;95:15475–15480.
64.
Liu J, Yu S, Litman D, Chen W, Weinstein LS: Identification of a methylation imprint mark within the mouse Gnas locus. Mol Cell Biol 2000;20:5808–5817.
65.
Campbell R, Gosden CM, Bonthron DT: Parental origin of transcription from the human GNAS1 gene. J Med Genet 1994;31:607–614.
66.
Yu S, Yu D, Lee E, Eckhaus M, Lee R, Corria Z, Accili D, Westphal H, Weinstein LS: Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsα) knockout mice is due to tissue-specific imprinting of the gsα gene. Proc Natl Acad Sci USA 1998;95:8715–8720.
67.
Schwindinger WF, Lawler AM, Gearhart JD, Levine MA: A murine model of Albright hereditary osteodystrophy. Endocrine Society, New Orleans, La., 1998, p. 480.
68.
Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, Bonthron DT: Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001;107:R31–R36.
69.
Fragoso MC, Latronico AC, Carvalho FM, Zerbini MC, Marcondes JA, Araujo LM, Lando VS, Frazzatto ET, Mendonca BB, Villares SM: Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 1998;83:2074–2078.
70.
Gorelov VN, Gyenes M, Neser F, Roher HD, Goretzki PE: Distribution of Gs-alpha activating mutations in human thyroid tumors measured by subcloning. J Cancer Res Clin Oncol 1996;122:453–457.
71.
O’Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NR: Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinogenesis 1991;4:345–349.
72.
Bastepe M, Pincus JE, Sugimoto T, Tojo K, Kanatani M, Azuma Y, Kruse K, Rosenbloom AL, Koshiyama H, Juppner H: Positional dissociation between the genetic mutation responsible for pseudohypoparathyroidism type Ib and the associated methylation defect at exon A/B: Evidence for a long-range regulatory element within the imprinted GNAS1 locus. Hum Mol Genet 2001;10:1231–1241.
73.
Juppner H, Schipani E, Bastepe M, Cole DE, Lawson ML, Mannstadt M, Hendy GN, Plotkin H, Koshiyama H, Koh T, Crawford JD, Olsen BR, Vikkula M: The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3. Proc Natl Acad Sci USA 1998;95:11798–11803.
74.
Jan de Beur SM, O’Connell JR, Peila R, Cho J, Deng Z, Kam S, Levine MA: The pseudohypoparathyroidism type lb locus is linked to a region including GNAS1 at 20q13.3. J Bone Miner Res 2003;18:424–433.
75.
Winter JSD, Hughes IA: Familial pseudohypoparathyroidism without somatic anomalies. Can Med Assoc J 1980;123:26–31.
76.
Bastepe M, Lane AH, Juppner H: Paternal uniparental isodisomy of chromosome 20q – and the resulting changes in GNAS1 methylation – as a plausible cause of pseudohypoparathyroidism. Am J Hum Genet 2001;68:1283–1289. 76 (b) Bastepe M, Frohlich LF, Hendy GN, Indridason OS, Josse RG, Koshiyama H, Korkko J, Nakamoto JM, Rosenbloom AL, Slyper AH, Sugimoto T, Tsatsoulis A, Crawford JD, Juppner H: Autosomal dominant pseudohypoparathyroidism type 1b is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control clement of GNAS. J Clin Invest 2003;112:1255–1263.
77.
Rao DS, Parfitt AM, Kleerekoper M, Pumo BS, Frame B: Dissociation between the effects of endogenous parathyroid hormone on adenosine 3′,5′-monophosphate generation and phosphate reabsorption in hypocalcemia due to vitamin D depletion: An acquired disorder resembling pseudohypoparathyroidism type II. J Clin Endocrinol Metab 1985;61:285–290.
78.
Wilson LC, Leverton K, Oude Luttikhuis ME, Oley CA, Flint J, Wolstenholme J, Duckett DP, Barrow MA, Leonard JV, Read AP, Trembath RC: Brachydactyly and mental retardation: An Albright hereditary osteodystrophy-like syndrome localized to 2q37. Am J Hum Genet 1995;56:400–407.
79.
Phelan MC, Rogers RC, Clarkson KB, Bowyer FP, Levine MA, Estabrooks LL, Severson MC, Dobyns WB: Albright hereditary osteodystrophy and del(2)(q37.3) in four unrelated individuals. Am J Med Genet 1995;58:1–7.
80.
Mallette LE, Kirkland JL, Gagel RF, Law WM Jr, Heath H III: Synthetic human parathyroid hormone-(1–34) for the study of pseudohypoparathyroidism. J Clin Endocrinol Metab 1988;67:964–972.
81.
Bhatt B, Burns J, Flanner D, McGee J: Direct visualization of single copy genes on banded metaphase chromosomes by nonisotopic in situ hybridization. Nucleic Acids Res 1988;16:3951–3961.
82.
Lindsay R, Nieves J, Henneman E, Shen V, Cosman F: Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1–34): Kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77:1535–1539.
83.
Stirling HF, Darling JA, Barr DG: Plasma cyclic AMP response to intravenous parathyroid hormone in pseudohypoparathyroidism. Acta Paediatr Scand 1991;80:333–338.
84.
Miura R, Yumita S, Yoshinaga K, Furukawa Y: Response of plasma 1,25-dihydroxyvitamin D in the human PTH(1–34) infusion test: An improved index for the diagnosis of idiopathic hypoparathyroidism and pseudohypoparathyroidism. Calcif Tissue Int 1990;46:309–313.
85.
Liu J, Litman D, Rosenberg MJ, Yu S, Biesecker LG, Weinstein LS: A GNAS1 imprinting defect in pseudohypoparathyroidism type IB. J Clin Invest 2000;106:1167–1174.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.